Ani Pharmaceuticals reported $30.08M in Selling and Administration Expenses for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Selling And Administration Expenses Change
Abbvie ABBV:US USD 3.3B 174M
Aerie Pharmaceuticals AERI:US USD 33.88M 5.73M
Ani Pharmaceuticals ANIP:US USD 30.08M 1.88M
Aurora Cannabis Inc ACB:CN CAD 45.04M 5.32M
Canopy Growth Corp WEED:CN CAD 125.74M 27.65M
Depomed DEPO:US USD 11.9M 1.56M
Eli Lilly And LLY:US USD 1.61B 10.9M
Emergent Biosolutions EBS:US USD 80.2M 900K
Endo International Ordinary Shares ENDP:US USD 192.46M 10.92M
Heron Therapeutics HRTX:US USD 28.18M 3.94M
Hikma Pharmaceutical HIK:LN USD 256M 0
Knight Therapeutics Inc GUD:CN CAD 23.87M 2.38M
Lannett LCI:US USD 16.7M 9.06M
Nektar Therapeutics NKTR:US USD 22.53M 1.09M
Novartis NVS:US USD 3.4B 185M
Omeros OMER:US USD 12.2M 1.72M
Perrigo Ordinary Shares PRGO:US USD 281M 57.1M
Sun Pharmaceuticals SUNP:IN INR 20.05B 702.9M
Teva Pharmaceutical TEVA:IT USD 777M 72M
Teva Pharmaceutical Industries TEVA:US USD 777M 72M